Pharmaceuticals

Roche

Genentech to Present New Data on Giredestrant's Potential in Early Breast Cancer Treatment at ASCO 2026

MPP and Roche Sign Voluntary License Agreement for Baloxavir Marboxil

Roche Signs Agreement with MPP to License Xofluza Generics in 129 Countries

AstraZeneca and Roche Diagnostics APAC Partner to Develop Advanced Pathology Solutions for Breast and Lung Cancer

FDA Approves Genentech's Tecentriq for ctDNA-Guided Adjuvant Treatment of Muscle-Invasive Bladder Cancer

Roche Launches New Blood Test for Alzheimer's Pathology with CE Certification

Roche Signs Final Acquisition Agreement for PathAI

Roche to Present Comprehensive Ophthalmology Data Package at ARVO Annual Meeting

Roche Subsidiary Genentech to Release New Efficacy Data for Vabysmo

Roche Holding AG (OTCMKTS:RHHBY) Short Interest Significantly Decreased

Swiss Multinational Corporations Adjust Diversity Policies in Response to US Pressure

Roche Reaffirms 2026 Earnings and Revenue Targets

Roche Reports 6% Strong Sales Growth at Constant Exchange Rates in Q1 2026

Roche Announces Results from Phase III METEOROID Trial for MOGAD

Roche Diagnostics Achieves Domestication to Counter Competition

Roche Genentech Announces Successful Phase 3 Clinical Trial Results for Fenebrutinib, Reducing Relapse Rate by Up to 59%

Roche's ENSPRYNG Reduces Relapse Risk by 68%

FDA Accepts Roche's Gazyva/Gazyvaro Application for Treating the Most Common Form of Lupus

Roche Subsidiary Agrees to Acquisition of Saga Diagnostics for Up to $595 Million

Roche Launches Phase III Study for Elevidys in Response to EMA Feedback

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

RHHBY

LABU

SBIO

ARKG

Roche will present new data on giredestrant at the ASCO 2026 Annual Meeting, highlighting its potential as a standard treatment for early breast cancer. Key studies include lidERA, showing a 30% reduction in disease recurrence risk, and persevERA, which indicates numerical improvement in progression-free survival with giredestrant plus palbociclib. Roche's focus also includes advancements in HER2-positive breast cancer and other cancer treatments, emphasizing their commitment to addressing significant patient needs.

StockTitan

Health Care Select Sector SPDR

iShares US Pharma

VG Health

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

ROCHE HOLDINGS AG

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | RHHBY Stock News

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

AstraZeneca

Daiichi Sankyo Company, Limited

Daiichi Sankyo

AstraZeneca PLC

FDA approves Enhertu for two HER2-positive early breast cancer indications

ILMN

The Cancer Biomarkers Market is projected to grow from USD 28.25 billion in 2026 to USD 54.48 billion by 2032, at a CAGR of 11.6%. The diagnostics segment will lead the market, while the consumables segment is expected to grow the fastest. North America is anticipated to dominate the market due to its healthcare infrastructure and high cancer incidence. Key players include Thermo Fisher, Roche, and Illumina.

prnewswire

Thermo Fisher Scentific

Illumina

SPDR S&P Health Equip

iShares US Medical Devices

Quest Diagnostics

Agilent Tech

10:30 ETCancer Biomarkers Market worth $54.48 billion by 2032 | MarketsandMarkets™

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News

Roche(RHHBY.US)

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | RHHBY Stock News

FDA approves Enhertu for two HER2-positive early breast cancer indications

10:30 ETCancer Biomarkers Market worth $54.48 billion by 2032 | MarketsandMarkets™

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment | RHHBY Stock News